Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-04-30
2000-09-05
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514183, A61K 3133, A61K 31555
Patent
active
061143200
ABSTRACT:
A method for inhibiting VEGF stimulated endothelial cell growth, such as associated with macular degeneration, and VEGF stimulated capillary permeability, such as associated with macular edema are disclosed, particularly using the isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2"-ethoxy)-3'"(O)-4'"-(N,N-dimethylamino)-butane)-bis -(3,3'-indoly 1)]-1(H)-pyrrole-2,5-dionehydrochloridesalt.
REFERENCES:
patent: 5057614 (1991-10-01), Davis et al.
patent: 5481003 (1996-01-01), Gillig et al.
patent: 5491242 (1996-02-01), Gillig et al.
patent: 5545636 (1996-08-01), Heath, Jr. et al.
patent: 5552396 (1996-09-01), Heath et al.
patent: 5621098 (1997-04-01), Heath, Jr. et al.
Kunisaki et al. "Vitamin E prevents diabetes-induced abnormal retinal blood flow via the diacylglycerolprotein kinase C pathway", Am. J. Physiol. vol. 269, No. 2, 1995 pp. E239-E246.
Aiello, et al., New England Jour. Medicine, 331(22):1480-1487 (1994).
Amin, et al., Invest Ophthalmol Vis Sci., 35:3178-3188 (1994).
Biotechnology Newswatch, Jan. 1, 1996.
Bird, Surv. Ophthalmol., 28:433-6 (1984).
Bundgaard, H., Design of Prodrugs, (1985).
Chan et al., Ophthalmology, 101:289-300 (1994).
Cunha-Vaz, Surv Ophthalmol. 28:485-92 (1984).
Freund et al., Amer. Jour. Ophthalmol., 115:786-791 (1993).
Friedman, et al., Amer. J. Kidney Dis., 26(1):202-208 (1995).
Henkind, Surv. Ophthalmol. 28:431-2 (1984).
Jampol, et al., Surv. Ophthalmol. 28:535-9 (1984).
Kirkpatrick et al., Br. J. Ophthalmol., 77:766-770 (1993).
Klein, et al., "Prevalence of Age Related Maculopathy: The Beaver Dam Study," Ophthalmology, 99(6):933-943, 1992).
Klein, Med. Clin. N. Am., 72:1415-1437 (1988).
Liebowitz HM, Krueer DE, Maunder LE, et al., "The Framingham Eye Study: VI Macular Degeneration," Surv. Opthalmol. 24 (supp 10:428-457, 1980).
Miwa, Drug Intell. Clin. Pharm., 20:548-550 (1986).
MPS Group, Arch Ophthalmol., vol. 109, pp. 1232-1241 (1991).
Raskin, et al., Ann. Int. Med., 117(3):226-233 (1992).
"Researchers Focus on Macular Degeneration: Common Eye Problems, Causes and Treatment Get New Attention" by Steven Sternberg, Washington Post Health, Oct. 31, 1995.
Yannuzzi, Surv Ophthalmol. 28:540-53 (1984).
Yannuzzi, et al., Opthalmology, 88:947-54 (1981).
Van Effenterre, et al., J. Francais D Ophtalmol., 16(11):602-610 (1993).
Peer B. Jacobson et al. "Anti-inflammatory Properties of Go 6820: A Selective Inhibitor of Protein Kinase C" Journal of Pharmacology and Experimental Therapeutics, Vo. 275, No. 2 1995 pp. 995-1002.
Aiello Lloyd P.
Jirousek Michael R.
King George L.
Vignati Louis
Ways Douglas Kirk
Caltrider Steven P.
Darkes Paul R.
Eli Lilly and Company
Fay Zohreh
Joslin Diabetes Center
LandOfFree
Therapeutic treatment for VEGF related ocular diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic treatment for VEGF related ocular diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic treatment for VEGF related ocular diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2212286